Here's a case for the biotech hybrid model, one that relies on a crack team of internal core talent complemented by broad reliance on external vendors.
- From QM To QMM For AI-Assisted Pharmaceutical Manufacturing Operations
- The Systems And Choreography Needed For Grade B ATMP Material Transfer
- Rethinking ATMP Assurance When Sterility Timelines, Reality Misalign
- Navigating GMP Biosafety Challenges In ATMP Manufacturing
- Ensuring Quality Of CGT Materials
- Zymeworks Shares Its Design Rationale (And Wins) In Early-Phase ADC Trials
- Ever Wonder What Running A $50B Capital Facilities Project Feels Like?
- Generative AI Can Write The Code, But Who Builds In The Quality?
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
The Importance Of Quality Proteins For Research, Development, And Manufacturing
Learn how validated testing, strict sourcing, and regulatory guidance help minimize endotoxin contamination risks and support reliable therapeutic development in advanced medicinal products.
-
Automation And Digital Solutions Can Help You Reach Your mRNA Manufacturing And Sustainability Goals
Explore how digital solutions help streamline mRNA manufacturing by reducing costs, improving efficiency, and supporting sustainability by creating paperless processes for emerging therapeutics.
-
Inside The Payer Perspective On Cell And Gene Therapy Coverage
Find out what 19 US payer organizations revealed about CGT coverage decisions, pre-approval engagement timelines, and the clinical evidence they need most to approve high-cost therapies.
-
Revolutionizing Drug Discovery From "Undruggables" To AI
Explore four current trends in drug discovery, how each trend addresses some of the most crucial challenges in drug discovery, and the obstacles to their widespread adoption.
-
Key Takeaways And Market Insights From The Inaugural ThinkLive Summit
The inaugural ThinkLive Cell and Gene Therapy Summit explored the industry’s dynamic landscape, highlighting collaboration, communication, and market access challenges.
-
The State Of Digital Maturity In Pharma And Medtech Manufacturing
Explore results from a study aiming to understand why numerous companies continue to rely on manual, paper-based systems, and gain insight into how your competitors are gaining a competitive advantage.
-
Guiding GLP-1 Participants Through The Challenge Of Retention
Learn how remote lifestyle coaching can combat high dropout rates in metabolic research by offering the support participants need to maintain adherence and ensure data integrity.
-
Digital Biomanufacturing, Now: From Digital Dreamer To Digital Doer
Discover how digital biomanufacturing is revolutionizing drug production by exploring strategies for integrating digital technologies to enhance efficiency and innovation in bioprocessing workflows.
-
Tailoring Viral Clearance Study Design
Viral‑clearance studies need phase‑appropriate design, strong virus stocks, modality‑specific risk assessment, and alignment with evolving regulations for reliable safety outcomes.
-
A Toolkit For Unraveling Protein Expression Patterns
Learn about a method that utilizes monoclonal antibodies and flow cytometry to analyze the metabolic state of individual immune cells, advancing immune research and immunotherapy.
NEWSLETTER ARCHIVE
- 04.11.26 -- Cell & Gene Best Of March
- 04.10.26 -- Ever Wonder What Running A $50B Capital Facilities Project Feels Like?
- 04.09.26 -- New Editing Modalities Driving Scalable Genomic Medicine
- 04.09.26 -- Cell And Gene Therapy CDMOs: On The Path To $75 Billion In Services?
- 04.08.26 -- Ensuring Quality Of CGT Materials
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections